Endologix

OverviewSuggest Edit

Endologix, Inc. is singularly focused on providing innovative, minimally invasive technologies for aortic disorders. The Company's product offering includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Designed around key issues with challenging anatomies, difficult access, and aneurysm sealing, Endologix products have been clinically proven in delivering positive patient outcomes. 

TypePublic
Founded1992
HQIrvine, CA, US
Websiteendologix.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Dec 2018)528(-21%)
Job Openings24
Revenue (FY, 2019)$143.4 M(-8%)
Share Price (Oct 2020)$0(-24%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Endologix

John Onopchenko

John Onopchenko

Chief Executive Officer and Director
Cindy Pinto

Cindy Pinto

Interim Chief Financial Officer
Reyna Fernandez

Reyna Fernandez

Chief Human Resources Officer
Jeff Brown

Jeff Brown

Chief Operations Officer
Michael Chobotov

Michael Chobotov

Chief Technology Officer
Jeffry Fecho

Jeffry Fecho

Chief Quality Officer
Show more

Endologix Office Locations

Endologix has offices in Irvine, Santa Rosa, Rosmalen, 's-Hertogenbosch and in 1 other location
Irvine, CA, US (HQ)
2 Musick
Santa Rosa, CA, US
3910 Brickway Blvd
's-Hertogenbosch, NL
Europalaan 30
Rosmalen, NL
40 Burgemeester Burgerslaan
Singapore, SG
1 Gateway Dr, #07-01 Westgate Tower
Show all (5)

Endologix Financials and Metrics

Endologix Revenue

Embed Graph
View revenue for all periods
Endologix's revenue was reported to be $143.37 m in FY, 2019
USD

Revenue (Q2, 2020)

24.8m

Gross profit (Q2, 2020)

14.2m

Gross profit margin (Q2, 2020), %

57%

Net income (Q2, 2020)

(26.1m)

EBIT (Q2, 2020)

(17.3m)

Market capitalization (1-Oct-2020)

4.2m

Closing stock price (1-Oct-2020)

0.0

Cash (30-Jun-2020)

18.5m

EV

382.2m
Endologix's current market capitalization is $4.2 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

192.9m181.2m156.5m143.4m

Revenue growth, %

26%(6%)(14%)

Cost of goods sold

69.1m59.8m64.6m52.3m

Gross profit

123.8m121.3m91.9m91.1m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

42.6m48.6m46.0m42.3m44.7m34.8m35.6m36.2m35.8m28.5m24.8m

Cost of goods sold

14.0m16.3m16.9m14.0m15.1m12.1m12.4m13.3m12.7m13.4m10.7m

Gross profit

28.6m32.2m29.1m28.3m29.6m22.6m23.2m23.0m23.1m15.1m14.2m

Gross profit Margin, %

67%66%63%67%66%65%65%63%64%53%57%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

26.1m58.0m23.5m41.6m

Accounts Receivable

1.8m22.4m

Inventories

41.2m45.2m30.4m26.4m

Current Assets

129.8m143.1m78.9m93.7m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

15.5m81.6m74.6m48.0m35.6m38.3m9.7m50.9m46.6m40.9m18.5m

Accounts Receivable

952.0k390.0k21.9m21.7m19.0m11.1m

Prepaid Expenses

2.3m2.1m

Inventories

42.7m43.6m42.7m45.8m42.8m42.3m30.2m30.7m30.9m24.5m25.9m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(154.7m)(66.4m)(79.7m)(64.8m)

Depreciation and Amortization

9.1m9.1m8.0m6.9m

Inventories

3.5m(3.0m)13.8m3.6m

Accounts Payable

(5.2m)(1.8m)(1.3m)3.1m
Quarterly
USDFY, 2016

Revenue/Employee

246.7k

Financial Leverage

3.2 x
Show all financial metrics

Endologix Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Endologix Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Endologix Online and Social Media Presence

Embed Graph

Endologix News and Updates

Worldwide Abdominal Aortic Aneurysm Treatment Industry to 2027 - Featuring Cardinal, Medtronic and Endologix Among Others

Dublin, Oct. 21, 2021 (GLOBE NEWSWIRE) -- The "Global Abdominal Aortic Aneurysm Treatment Market Size By Type, By Application, By Geographic Scope And Forecast" report has been added to ResearchAndMarkets.com's offering. Abdominal Aortic Aneurysm Treatment Market was valued at USD 1.74 Billion in …

United States // Endologix, Inc. to Present at the SVB Leerink Global Healthcare Conference

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-li…

Endologix Blogs

Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA

The TORUS 2 study is a prospective, single-arm trial of 188 patients to evaluate safety and effectiveness of the TORUS Stent Graft System. in the treatment of PAD in the SFA and proximal popliteal arteries. IRVINE, Calif. November 23, 2021—Endologix LLC, a privately held global medical device compan…

Endologix Names Dr. Matthew Thompson President and CEO

NOVEMBER 10, 2021 – IRVINE, CA Endologix LLC., a privately held global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease, announced today the appointment of Dr. Matthew Thompson, as President and Chief…

Endologix Initiates Randomized Study of ALTO® Abdominal Stent Graft System

JAGUAR Study Evaluates ALTO Compared to Other Commercially Available EVAR Devices IRVINE, Calif.—Sept. 29, 2021—Endologix LLC, a leader in the treatment of vascular disease, today announced that the first patient has been enrolled in the company’s JAGUAR study to compare outcomes for the company’s A…

Endologix LLC Receives FDA Breakthrough Device Designation for ChEVASTM System

Investigational EVAS System Designed for Patients with Complex Abdominal Aortic Aneurysm IRVINE, Calif.—July 19, 2021—Endologix LLC, a leader in the treatment of vascular disease, today announced the company’s ChEVASTM (Chimney EndoVascular Aneurysm Sealing) System has been granted a Breakthrough De…

Endologix LLC Announces Launch of ALTO® Abdominal Stent Graft System in Canada and Argentina Company Expands Global Reach with Latest Endovascular Aneurysm Repair (EVAR) Technology

IRVINE, Calif.—(BUSINESS WIRE)—May 11, 2021—Endologix LLC, a leader in the treatment of vascular disease, today announced the first implant of its ALTO® Abdominal Stent Graft in Canada following recent approval from Health Canada. ALTO was also recently approved for commercial sale in Argentina. “We…

Endologix LLC Announces Acquisition of PQ Bypass, Inc.

Company Expands Vascular Reach to Treat Unmet Needs of Both AAA and PAD Patients IRVINE, Calif.—(BUSINESS WIRE)—April 13, 2021—Endologix LLC, a leader in the treatment of vascular disease, today announced it has completed the acquisition of PQ Bypass, Inc., a privately held medical technology compan…
Show more

Endologix Frequently Asked Questions

  • When was Endologix founded?

    Endologix was founded in 1992.

  • Who are Endologix key executives?

    Endologix's key executives are John Onopchenko, Cindy Pinto and Reyna Fernandez.

  • How many employees does Endologix have?

    Endologix has 528 employees.

  • What is Endologix revenue?

    Latest Endologix annual revenue is $143.4 m.

  • What is Endologix revenue per employee?

    Latest Endologix revenue per employee is $271.5 k.

  • Who are Endologix competitors?

    Competitors of Endologix include CSL, Mcneil and The Searle Company.

  • Where is Endologix headquarters?

    Endologix headquarters is located at 2 Musick, Irvine.

  • Where are Endologix offices?

    Endologix has offices in Irvine, Santa Rosa, Rosmalen, 's-Hertogenbosch and in 1 other location.

  • How many offices does Endologix have?

    Endologix has 5 offices.